Nanotechnology and nanocarrier-based drug delivery as the potential therapeutic strategy for glioblastoma multiforme: An update

Jen Fu Hsu, Shih Ming Chu, Chen Chu Liao, Chao Jan Wang, Yi Shan Wang, Mei Yin Lai, Hsiao Chin Wang, Hsuan Rong Huang, Ming Horng Tsai*

*此作品的通信作者

研究成果: 期刊稿件文獻綜述同行評審

86 引文 斯高帕斯(Scopus)

摘要

Glioblastoma multiforme (GBM) is the most common and malignant brain tumor with poor prognosis. The heterogeneous and aggressive nature of GBMs increases the difficulty of current standard treatment. The presence of GBM stem cells and the blood brain barrier (BBB) further contribute to the most important compromise of chemotherapy and radiation therapy. Current suggestions to optimize GBM patients’ outcomes favor controlled targeted delivery of chemotherapeutic agents to GBM cells through the BBB using nanoparticles and monoclonal antibodies. Nanotechnology and nanocarrier-based drug delivery have recently gained attention due to the characteristics of biosafety, sustained drug release, increased solubility, and enhanced drug bioactivity and BBB penetrability. In this review, we focused on recently developed nanoparticles and emerging strategies using nanocarriers for the treatment of GBMs. Current studies using nanoparticles or nanocarrier-based drug delivery system for treatment of GBMs in clinical trials, as well as the advantages and limitations, were also reviewed.

原文英語
文章編號195
頁(從 - 到)1-22
頁數22
期刊Cancers
13
發行號2
DOIs
出版狀態已出版 - 02 01 2021

文獻附註

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

指紋

深入研究「Nanotechnology and nanocarrier-based drug delivery as the potential therapeutic strategy for glioblastoma multiforme: An update」主題。共同形成了獨特的指紋。

引用此